Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria.
Biotechnol J. 2010 Jan;5(1):17-23. doi: 10.1002/biot.200900267.
Recent outbreaks of influenza A highlight the importance of rapid and sufficient supply for pandemic and inter-pandemic vaccines. Classical manufacturing methods for influenza vaccines fail to satisfy this demand. Alternatively, cell culture-based production systems and virus-like particle (VLP)-based technologies have been established. We developed swine-origin pandemic H1N1 influenza VLPs consisting of hemagglutinin (A/California/04/2009) and matrix protein. Hemagglutinin and matrix protein were co-expressed in insect cells by the baculovirus expression system. VLPs were harvested from infection supernatants, purified and used for intraperitoneal immunization of BALB/c mice. Immunization induced high serum antibody titers against A/California/04/2009 as well as hemagglutination inhibiting antibodies. Additionally, we compared VLP production in two different insect cell lines, Sf9 and BTI-TN5B1-4 (High Five). Taken together VLPs represent a potential strategy for the fight against new pandemic influenza viruses.
最近的甲型流感爆发凸显了快速和充足供应大流行性流感疫苗和大流行间期疫苗的重要性。流感疫苗的经典制造方法无法满足这一需求。相反，已经建立了基于细胞培养的生产系统和基于病毒样颗粒（VLP）的技术。我们开发了由血凝素（A/加利福尼亚/04/2009）和基质蛋白组成的猪源大流行性 H1N1 流感 VLP。通过杆状病毒表达系统在昆虫细胞中共同表达血凝素和基质蛋白。从感染上清液中收获 VLP，纯化并用于 BALB/c 小鼠的腹腔免疫。免疫诱导了针对 A/加利福尼亚/04/2009 的高血清抗体滴度以及血凝抑制抗体。此外，我们比较了两种不同的昆虫细胞系 Sf9 和 BTI-TN5B1-4（High Five）中的 VLP 生产。总之，VLP 代表了对抗新的大流行性流感病毒的一种潜在策略。
